April 5, 2022Open Access
Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
View Full Paper
Ask AI
Bookmark
Share
Key result
Stage III breast cancer is linked to ~22% higher circulating PCSK9 levels versus benign lesions.
- P=0.031
- n=46
Why the study?
Circulating levels of the targets of a new generation of lipid-lowering drugs (PCSK9, ANGPTL3, and Lp(a)) have not been fully investigated in cancers.
Comparison
Stage III breast cancer vs premalignant or benign breast lesions
Design
Age-matched case-control study
Authors
Discussion
Loading...
Member takes
Implication
PCSK9 elevation was associated with stage III breast cancer; leaves open causal role and any therapeutic implications.
Study Design
Type
Case-Control (n=46)
Multicenter
No
Structured PICO
P
Population
46 women, including 23 with stage III breast cancer (ductal, lobular or mixed) and 23 age-matched controls with premalignant (stage 0, n=9) or benign (n=14) breast lesions.
O
Outcome
Circulating levels of PCSK9, ANGPTL3, and Lp(a)surrogate
Main Result
Absolute Event Rate: 95.9% vs 78.5%
p-value: p=0.031
Circulating PCSK9 levels are elevated in women with stage III breast cancer compared to those with benign lesions, suggesting a potential association between PCSK9 and breast cancer severity.
Limitations
- Limited amount of plasma samples (small sample size)
- Control group merged non-cancerous with early-stage cancerous samples
- Information on medications such as statins was unknown
- Ethnical origins of women were not documented
- Small sample size
Cite This Study
Chong et al. (2022) conducted a case-control in Stage III breast cancer (n=46). Stage III breast cancer vs. Benign breast lesion was evaluated on Circulating PCSK9 levels (ng/mL) (p=0.031). PCSK9 levels were significantly higher in women with stage III breast cancer compared to age-matched counterparts presenting a benign lesion (95.9 vs 78.5 ng/mL).
View Full Paper
Ask AI
Bookmark
Share